MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2159-8290.cd-16-1406

Медицинская библиотека · Cancer discovery · 2018

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

Miyamoto David T, Lee Richard J, Kalinich Mark, LiCausi Joseph A, Zheng Yu, Chen Tianqi, Milner John D, Emmons Erin, Ho Uyen, Broderick Katherine, Silva Erin, Javaid Sarah, Kwan Tanya Todorova, Hong Xin, Dahl Douglas M, McGovern Francis J, Efstathiou Jason A, Smith Matthew R, Sequist Lecia V, Kapur Ravi, Wu Chin-Lee, Stott Shannon L, Ting David T, Giobbie-Hurder Anita, Toner Mehmet, Maheswaran Shyamala, Haber Daniel A

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод в очереди

Аннотация

Blood-based biomarkers are critical in metastatic prostate cancer, where characteristic bone metastases are not readily sampled, and they may enable risk stratification in localized disease. We established a sensitive and high-throughput strategy for analyzing prostate circulating tumor cells (CTC) using microfluidic cell enrichment followed by digital quantitation of prostate-derived transcripts. In a prospective study of 27 patients with metastatic castration-resistant prostate cancer treated with first-line abiraterone, pretreatment elevation of the digital CTCM score identifies a high-risk population with poor overall survival (HR = 6.0; P = 0.01) and short radiographic progression-free survival (HR = 3.2; P = 0.046). Expression of HOXB13 in CTCs identifies 6 of 6 patients with ≤12-month survival, with a subset also expressing the ARV7 splice variant. In a second cohort of 34 men with localized prostate cancer, an elevated preoperative CTCL score predicts microscopic dissemination to seminal vesicles and/or lymph nodes (P < 0.001). Thus, digital quantitation of CTC-specific transcripts enables noninvasive monitoring that may guide treatment selection in both metastatic and localized prostate cancer.Significance: There is an unmet need for biomarkers to guide prostate cancer therapies, for curative treatment of localized cancer and for application of molecularly targeted agents in metastatic disease. Digital quantitation of prostate CTC-derived transcripts in blood specimens is predictive of abiraterone response in metastatic cancer and of early dissemination in localized cancer. Cancer Discov; 8(3); 288-303. ©2018 AACR.See related commentary by Heitzer and Speicher, p. 269This article is highlighted in the In This Issue feature, p. 253.

Для цитирования: Miyamoto David T, Lee Richard J, Kalinich Mark, LiCausi Joseph A, Zheng Yu, Chen Tianqi, Milner John D, Emmons Erin, Ho Uyen, Broderick Katherine, Silva Erin, Javaid Sarah, Kwan Tanya Todorova, Hong Xin, Dahl Douglas M, McGovern Francis J, Efstathiou Jason A, Smith Matthew R, Sequist Lecia V, Kapur Ravi, Wu Chin-Lee, Stott Shannon L, Ting David T, Giobbie-Hurder Anita, Toner Mehmet, Maheswaran Shyamala, Haber Daniel A. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.. Cancer discovery. 2018. DOI: 10.1158/2159-8290.cd-16-1406.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.